IMPAX LABORATORIES INC
			Symbol			IPXL

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Impax Laboratories Confirms Patent Challenge Relating to TRICOR® 48mg and 145mg Tablets

2009-10-30 10:45 ET - News Release

Company Website: http://www.impaxlabs.com
HAYWARD, Calif. -- (Business Wire)

Impax Laboratories, Inc.(NASDAQ:IPXL) today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.

Impax filed its Abbreviated New Drug Application (“ANDA”) containing a Paragraph IV certification for a generic version of TRICOR® with the U.S. Food & Drug Administration (“FDA”). Following receipt of the notice from the FDA that Impax’s ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owners of its Paragraph IV certification.

On October 29, 2009, Abbott Laboratories and Laboratoires Fournier S.A. filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.